Forum Financial Management LP Buys Shares of 1,680 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Forum Financial Management LP bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,680 shares of the biotechnology company’s stock, valued at approximately $265,000.

Other institutional investors have also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. lifted its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 75 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after purchasing an additional 120 shares during the last quarter. WCM Investment Management LLC grew its position in shares of Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares in the last quarter. Finally, New York Life Investment Management LLC increased its holdings in shares of Sarepta Therapeutics by 1.7% in the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company’s stock valued at $959,000 after purchasing an additional 166 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 1.1 %

Shares of NASDAQ:SRPT opened at $135.78 on Friday. The firm has a market capitalization of $12.83 billion, a PE ratio of 1,234.36 and a beta of 0.89. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The firm’s 50-day moving average is $145.03 and its two-hundred day moving average is $133.00.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period in the prior year, the firm earned ($0.27) EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. Analysts predict that Sarepta Therapeutics, Inc. will post 3.76 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Piper Sandler dropped their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Leerink Partners raised their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price target for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Finally, Robert W. Baird lifted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $186.22.

Insider Transactions at Sarepta Therapeutics

In related news, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The disclosure for this purchase can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.